Enpatoran is a selective antagonist of the TLR7 and TLR8 receptors, which play key roles in the activation of the innate immune system. Its primary application is in the treatment of autoimmune and inflammatory diseases, particularly systemic lupus erythematosus (SLE) and cutaneous lupus. By inhibiting TLR7 and TLR8 signaling, Enpatoran reduces the overproduction of type I interferons and other pro-inflammatory cytokines that drive disease pathology. This mechanism helps control disease activity, especially in patients with skin involvement, and may improve symptoms such as rashes, joint pain, and fatigue. Enpatoran is being developed as an oral therapy, offering potential for convenient dosing and improved patient compliance compared to injectable biologics. Clinical trials are evaluating its efficacy and safety in moderate to severe lupus, positioning it as a promising targeted therapy in autoimmune disease management.